more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$318.02 USD

+0.10 (0.03%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veeva Systems (VEEV) Q2 Earnings Beat Estimates, '22 View Up

by Zacks Equity Research Published on September 02,2021

Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both its segments.

Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise

by Zacks Equity Research Published on August 30,2021

Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.

Cooper Companies (COO) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research Published on August 27,2021

Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.

Phibro (PAHC) Q4 Earnings Match Estimates, Margins Down

by Zacks Equity Research Published on August 27,2021

Phibro (PAHC) sees revenue growth in fourth-quarter fiscal 2021 due to strength in all three segments.

What's in Store for Patterson Companies' (PDCO) Q1 Earnings?

by Zacks Equity Research Published on August 26,2021

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect improvement at Dental segment.

Is West Pharmaceutical Services (WST) a Great Growth Stock?

by Zacks Equity Research Published on August 26,2021

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical Services (WST).

WSTPositive Net Change

medical

Here is Why Growth Investors Should Buy West Pharmaceutical (WST) Now

by Zacks Equity Research Published on August 25,2021

West Pharmaceutical (WST) could produce exceptional returns because of its solid growth attributes.

WSTPositive Net Change

Align Technology (ALGN) at a 52-Week High: What's Driving It?

by Zacks Equity Research Published on August 25,2021

Strong performance by the Clear Aligners and Systems & CAD/CAM Services segments drove the top line for Align Technology (ALGN).

Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research Published on August 24,2021

Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.

earnings

The Zacks Analyst Blog Highlights: Microsoft, EMCOR, West Pharmaceutical Services, Deere and Texas Instruments

by Zacks Equity Research Published on August 23,2021

The Zacks Analyst Blog Highlights: Microsoft, EMCOR, West Pharmaceutical Services, Deere and Texas Instruments

Here's Why You Should Add Omnicell (OMCL) to Your Portfolio

by Zacks Equity Research Published on August 23,2021

Omnicell (OMCL) ended the second quarter with better-than-expected results, with the top line registering solid year-over-year growth.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

by Zacks Equity Research Published on August 23,2021

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

LabCorp (LH) Inks Deal to Assess Disparities in Drug Development

by Zacks Equity Research Published on August 20,2021

LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.

Sustainability Trends Boost ESG Investing: 5 Green Picks

by Sreoshi Bera Published on August 20,2021

ESG investing will get a boost from sustainability trends, which calls for investing in Microsoft (MSFT), EMCOR Group (EME), West Pharmaceutical (WST), Deere (DE) & Texas Instruments (TXN).

West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

by Zacks Equity Research Published on August 18,2021

Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.

Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up

by Zacks Equity Research Published on August 18,2021

Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.

West Pharmaceutical (WST) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on August 16,2021

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.